Abstracts tagged "Infection"

Abstract Number: 1830 • ACR Convergence 2020
Adverse Drug Reactions to Trimethoprim-sulfamethoxazole as a Prophylactic Agent Against Pneumocystis Pneumonia in Patients with Systemic Lupus Erythematosus: anti-Sm Antibody as a Possible Risk Factor
Shinji Izuka¹, Hiroyuki Yamashita², Yuko Takahashi² and Hiroshi Kaneko², ¹Devision of Rheumatic Disease, National Center for Global Health and Medicine, Toshima-Ku, Tokyo, Japan, ²Devision of Rheumatic Disease, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan
Background/Purpose: Pneumocystis pneumonia (PCP) is a life-threatening infection in immunocompromised patients, including those with connective tissue diseases (CTDs), treated with corticosteroids or immunosuppressive agents. Trimethoprim-sulfamethoxazole…
Abstract Number: 0016 • ACR Convergence 2020
Differential Characteristics in Inflammatory Rheumatologic Patients with Severe and Mild COVID-19 Infection
Paula García Escudero¹, Claudia Stoye², Orlando Pompei fernández², Marta González Fernández¹, Joaquín María Belzunegui Otano³, Juan Ramón De Dios², Belén Álvarez Rodríguez², Elena Garmendia Sánchez¹, Susana Gil², Ana Ruibal-Escribano⁴, Margarida Vasques Rocha², Francisco García Llorente⁵, César Antonio Egües⁶, Edurne Guerrero⁷ and Jaime Calvo-Alén², ¹Hospital Universitario Cruces, Barakaldo, Spain, ²Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, ³Rheumatology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Spain, ⁴Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, ⁵Hospital Universitario de Galdakao, Galdakao, Pais Vasco, Spain, ⁶Hospital Universitario Donostia, Donostia-San Sebastián, Pais Vasco, Spain, ⁷Hospital Alto Deba, Arrasate, Pais Vasco, Spain
Background/Purpose: SARS COV 2 pandemic has been an issue which has challenged the health care systems around the world. Rheumatology has been involved in two…
Abstract Number: 0554 • ACR Convergence 2020
Increased Burden of Painful Arthritis and Rheumatism Following the Chikungunya Epidemic 2006: India Rural Population Survey 2018
Arvind Chopra¹, Ravi Ghorpade², Anuradha Venugopalan¹, Manjit Saluja¹ and Kiran Adam¹, ¹Center for Rheumatic Diseases, Pune, India, ²Center for Rheumatic Diseases, Pune
Background/Purpose: A spectrum of post Chikungunya (Chik) arthritis , often RA like, were referred to an urban rheumatology centre (Pune India)during the 2006 epidemic (Arthritis…
Abstract Number: 1010 • ACR Convergence 2020
Infection and Malignancy Outcomes in Patients with RA Treated with Abatacept: Results from a Multinational Surveillance Study
Alyssa Dominique¹, Merete Hetland², Axel Finckh³, Jacques-Eric Gottenberg⁴, Florenzo Iannone⁵, Roberto Caporali⁶, Dan Nordstrom⁷, M Victoria Hernandez⁸, Carlos Sanchez-Piedra⁹, Fernando Sanchez-Alonso⁹, Karel Pavelka¹⁰, Zlatuše Křístková¹¹ and Teresa Simon¹², ¹Bristol-Myers Squibb Company, Princeton, NJ, ²The DANBIO Registry, Rigshospitalet, Glostrup, Denmark, ³Division of Rheumatology, University Hospitals of Geneva, Geneva, Switzerland, ⁴Strasbourg University Hospital, Strasbourg, France, ⁵DETO-Rheumatology Unit, University of Bari, Bari, Italy, ⁶Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ⁷Helsinki University Hospital and Helsinki University, Helsinki, Finland, ⁸Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain, ⁹Biobadaser, Research Unit, Sociedad Española de Reumatología, Madrid, Spain, ¹⁰Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹¹Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic, ¹²Bristol-Myers Squibb Company (at time of analysis), Princeton, NJ
Background/Purpose: Compared with the general population, patients with RA are at an increased risk of infection and certain malignancies, which may be increased further with…
Abstract Number: 1835 • ACR Convergence 2020
Evaluation of Low Dose Glucocorticoid Effects on Infection Occurrence in Systemic Lupus Erythematosus Patients
Kazuya Abe¹, Nobuyuki Yajima², Yuichi Ishikawa³, Yasuhiko Kita⁴, Ken-ei Sada⁵, Ryusuke Yoshimi⁶, Yasuhiro Shimojima⁷, Shigeru Ohno⁸, Hiroshi Kajiyama⁹, Kunihiro Ichinose¹⁰, Shuzo Sato¹¹ and Michio Fujiwara¹², ¹Department of Rheumatology, Yokohama Rosai Hospital, Chiba, Japan, ²Division of Rheumatology, Department of Internal Medicine, Showa University School of Medicine, Tokyo, Japan, ³Department of Rheumatology, Yokohama Rosai Hospital, Tokyo, Japan, ⁴Department of Rheumatology, Yokohama Rosai Hospital, kanagawa, ⁵Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan, ⁶Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁷Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan, ⁸Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, ⁹Department of Rheumatology and Applied Immunology Faculty of Medicine, Saitama Medical University, Iruma-gun, Saitama, Japan, ¹⁰Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ¹¹Fukushima Medical University School of Medicine, Department of Rheumatology, Fukushima, Japan, ¹²Department of Rheumatology, Yokohama Rosai Hospital, Kanagawa, Japan
Background/Purpose: Infection is major cause of morbidity and mortality in systemic lupus erythematosus (SLE) patient. The past exploratory study suggested various infection risk in SLE…
Abstract Number: 008 • 2020 Pediatric Rheumatology Symposium
Incidence and Risk Factors of Hypogammaglobulinemia and Infectious Complications Associated with Rituximab Use in Pediatric Rheumatic Diseases
Mei-Sing Ong¹, Deborah Rothman ² and Marc Natter ³, ¹Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, ²Massachusetts General Hospital, Springfield, ³Boston Children's Hospital, Boston
Background/Purpose: B-cell depletion therapy has increasingly been used for the treatment of childhood-onset rheumatic diseases. Previous studies investigating whether rituximab results in increased infections have…
Abstract Number: 069 • 2020 Pediatric Rheumatology Symposium
Rheumatic Fever in a Tertiary Medical Center – 25 Years of Follow Up
Liora Harel ¹, Gil Amarilyo ² and mohammad hammad saied³, ¹Schneider Hospital, Tel Aviv University, Petah-Tiqva, Israel, ²Schneider Hospital, Tel Aviv University, Kibbutz Magal, Israel, ³Schneider Medical Center, Kaboul village 24963, Israel
Background/Purpose: Rheumatic Fever (RF) occurs after a pharyngeal infection caused by group A-B-hemolytic streptococci.Its principal clinical significance is causing carditis at the acute phase of…
Abstract Number: 138 • 2020 Pediatric Rheumatology Symposium
Serious Infection Risk in Pediatric Patients with Low Immunoglobulin Levels Following Rituximab Treatment for Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
Simone Melega ¹, Paul Brogan², Gavin Cleary ³, Aimee Hersh ⁴, Ozgur Kasapcopur ⁵, Satyapal Rangaraj ⁶, Rae Yeung ⁷, Andrew Zeft ⁸, Jennifer Cooper ⁹, Pooneh Pordeli ¹⁰, Petra Kirchner ¹¹ and Patricia Lehane ¹², ¹F. Hoffmann-La Roche, Ltd., Basel, Switzerland, ²UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ³Alder Hey Children's Hospital, Liverpool, United Kingdom, ⁴University of Utah Primary Children's Hospital, Salt Lake City, ⁵Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Cerrahpasa, Turkey, ⁶Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, ⁷The Hospital for Sick Children, Toronto, Canada, ⁸The Cleveland Clinic - Center for Pediatric Rheumatology & Immunology, Cleveland, Ohio, ⁹University of Colorado, Children's Hospital Colorado, Denver, ¹⁰F. Hoffmann-La Roche, Ltd., Mississauga, Canada, ¹¹F. Hoffmann-La Roche Ltd., Birsfelden, Switzerland, ¹²Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: Low immunoglobulin (Ig) levels can occur after rituximab treatment, but the clinical significance is not completely understood. Not all patients (pts) who develop low…
Abstract Number: 2103 • 2019 ACR/ARP Annual Meeting
Anti-TNF Therapy in Patients with HIV Infection
Joanna Marco¹ and Alison Bays ², ¹University of Washington, Seattle, WA, ²University of Washington Division of Rheumatology, Seattle, WA
Background/Purpose: Patients with Human Immunodeficiency Virus (HIV) infection may benefit from the use of anti-Tumor Necrosis Factor (TNF) therapy in the setting of inflammatory disease,…
Abstract Number: 2107 • 2019 ACR/ARP Annual Meeting
Comparison of the Management and Prognosis of Pneumonia in Patients with and Those Without Rheumatoid Arthritis Using the Japanese Diagnosis Procedure Combination Database
Eishi Uechi¹ and Kiyohide Fushimi ², ¹Tomishiro Central Hospital, Tomigusuku city, Okinawa, Japan, ²Tokyo Medical and Dental University Graduate School, Bunkyo-ku, Tokyo, Japan
Background/Purpose: Pneumonia is a common cause of death not only in the general population but also in patients with rheumatoid arthritis (RA). In particular, patients…
Abstract Number: 2109 • 2019 ACR/ARP Annual Meeting
Are Immunosuppressants a Risk Factor Associated with Mycobacterium Tuberculosis Infection in Colombian Patients with Systemic Lupus Erythematosus? A Case-control Study
Jaime Coral-Enriquez ¹, Mauricio Restrepo ², Gloria Vasquez ³, Carlos H Muñoz-Vahos ⁴, Daniel Jaramillo ⁵, Adriana Vanegas-García ⁴, Ruth Eraso ⁶, Johanna Hernández ⁷, Fabian Jaimes ⁸ and Luis Gonzalez², ¹Grupo de Reumatología, Universidad de Antioquia, Medellin, Colombia, ²Grupo de Reumatología, Division of Rheumatology, Department of Internal Medicine, School of Medicine Universidad de Antioquia, Medellín, Colombia, ³University of Antioquia, Medellin, Antioquia, Colombia, ⁴Grupo de Reumatología, Universidad de Antioquia, Medellín, Antioquia, Colombia, ⁵Rheumatology unit, Hospital Universitario San Vicente Fundación, Medellin, Colombia, ⁶Grupo de Reumatología, Universidad de Antioquia; Pediatric rheumatology unit, Hospital Pablo Tobón Uribe, Medellin, Colombia, ⁷Division of Rheumatology, Pediatric Department, School of Medicine, Universidad de Antioquia, Medellín, Colombia, ⁸Department of Epidemiology, Hospital Universitario San Vicente Fundación, Universidad de Antioquia, Medellín, Colombia, Medellín, Colombia
Background/Purpose: Tuberculosis (TB) infection is an important cause of morbidity and mortality in systemic lupus erythematosus (SLE) patients, especially in developing countries. Previous studies have…
Abstract Number: 2122 • 2019 ACR/ARP Annual Meeting
Outcomes and Risk Factors in Septic Arthritis with Underlying Rheumatic Conditions
Soumyasri Kambhatla¹, Estefania Gauto-Mariotti ² and Augustine Manadan ³, ¹John H. Stroger Hospital of Cook County, Chicago, ²John H Stroger Hospital of Cook County, Chicago, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Septic arthritis is known to cause significant morbidity due to joint destruction and mortality if timely and adequate treatment is not given. In this study,…
Abstract Number: 2125 • 2019 ACR/ARP Annual Meeting
Rheumatic Fever in a Tertiary Medical Center – 25 Years of Follow Up
mohammad hammad saied¹, Liora Harel ², Gil Amarilyo ³, rotem tal ⁴ and Razi Zidani ⁵, ¹schneider medical center, kaboul village, Israel, ²Tel Aviv University, Tel Aviv, Israel, ³schneider medical center, petach tekva, ⁴schneider medical center, ramat gan, Israel, ⁵tel aviv university, Tamra, Israel
Background/Purpose: Rheumatic Fever (RF) occurs after a pharyngeal infection caused by group A-B-hemolytic streptococci.Its principal clinical significance is causing carditis at the acute phase of…
Abstract Number: 2521 • 2019 ACR/ARP Annual Meeting
Rituximab Treatment Is Not Associated with Increased Risk of Infection or Mortality in Refractory SLE Patients: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)
Stephen McDonald¹, Eoghan McCarthy ², Aysun Aksoy ³, Ben Parker ⁴ and Ian Bruce ⁵, ¹University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom; Manchester University Foundation Trust, The Kellgren Centre, Manchester, United Kingdom, Belfast, Northern Ireland, United Kingdom, ²Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, England, United Kingdom, ³Marmara University Faculty of Medicine, Division of Internal Medicine, Department of Rheumatology, Istanbul, Turkey; University of Manchester, Division of Musculoskeletal and Dermatological Sciences, Manchester, United Kingdom, Istanbul, Istanbul, Turkey, ⁴University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom; Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, United Kingdom, ⁵University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom
Background/Purpose: Mortality in Systemic Lupus Erythematosus (SLE) is increased compared to the general population. We sought to investigate mortality rates and associated factors in a…
Abstract Number: 2583 • 2019 ACR/ARP Annual Meeting
Prevalence and Risk Factors of Herpes Zoster Reactivation in Patients with Biopsy Proven Lupus Nephritis Undergoing Immunosuppressive Therapies
Chi Chiu Mok¹, Kar Li Chan ², Sau Mei Tse ² and Ling Yin Ho ², ¹Department of Medicine, Tuen Mun Hospital, Hong Kong, China (People's Republic), ²Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the prevalence of Herpes Zoster (HZ) reactivation in patients with biopsy confirmed lupus nephritis (LN) undergoing immunosuppressive therapies.Methods: Patients who had biopsy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].